Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 651

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 651
---
 of $10,526, a total of $5,995 already paid by TuHURA to Kineta is able to be credited towards the cash component of the aggregate Merger Consideration in the Mergers (consisting of the first exclusivity payment of $5,000 already made by TuHURA in July 2024, the extension payments made in connection with the Exclusivity Agreement of $300 paid by TuHURA in October 2024, and the Existing Advances already made by TuHURA to Kineta in connection with the Exclusivity Agreement in the aggregate amount of $695 which were loaned by TuHURA prior to the execution of the CTF Agreement and the Merger Agreement but were also incorporated thereon to aggregate with any forthcoming Advances made under the CTF Agreement). After incorporating the current estimated working capital deficit and creditable payments already made by TuHURA to Kineta, the estimated amount of cash to be paid at Closing for the cash component of the aggregate Merger Consideration (the “Closing Adjusted Cash Consideration”) is currently estimated to be $4,531. The actual Closing Adjusted Cash Consideration paid is subject to adjustment pursuant to the Merger Agreement based on the final net working capital deficit or surplus of Kineta at the Closing and certain subsequent working capital loans made by TuHURA to Kineta between the date of the Merger Agreement and closing of the Mergers not related to the funding under the CTF Agreement with such loans and their terms made in contemplation within the Merger Agreement. The estimated share consideration, which is ultimately subject to adjustment pursuant to the Merger Agreement, to be paid to Kineta stockholders will consist of an aggregate of up to approximately 3,476,566 shares of TuHURA Common Stock, which is calculated by using the top-lineshare value of, $20 million and dividing by the TuHURA Share Value (e.g. 3,476,566 shares x $5.7528 equals $20 million). 423

<div align='center'>**NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**</div>

**As additional estimated contingent consideration, Kineta stockholders will be entitled to receive their pro rata share of certain payments in cash that Kineta may receive after the Closing of the Mergers from the potential pre-closing sale by Kineta of certain non-KVA12123 products and technologies (the “Disposed Asset Payment Right”